Ascentage Pharma Group International · HKEX:6855
Ascentage Pharma Group International — Q2 2026 Earnings Presentation
27 slides from Ascentage Pharma Group International's earnings presentation, Aug 20, 2026
Slide 1: 2026 Interim Results and Business Update
6855 AAPG Ascentage 2026 Interim Results and Business Update August 20, 2026
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation has been prepared by Ascentage Pharma Group International (the “Company”) and includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of
Slide 3: Agenda
AGENDA 1 Business Update 2 R&D Highlights 3 Financial Results 4 Q&A 3
Slide 4: Business Update
Kscentage Business Update
Slide 5: 1H 2026: Strong Progress Across Strategic Priorities
1H 2026: Strong Progress Across Strategic Priorities Financial & Business Update • Total revenue of $44.5M, up 29% YoY1; of which were product sales of $41.6M;cash runway through 2027 • Appointed Dr. Faiçal Miyara as Chief Business Officer and Mr. Jim Ziegler as Chief Commercial Officer • Removal of
Slide 6: Established Commercial-Stage Portfolio with Highly De-risked, Late-Stage Pipeline
Established Commercial-Stage Portfolio with Highly De-risked, Late-Stage Pipeline Olverembatinib 3rd Gen BCR-ABL Inhibitor Lisaftoclax Bcl-2 Selective Inhibitor • Approved for CML-CP since 2021 • Approved as single-agent in post-BTK CLL/SLL • Real-world long-term safety and efficacy data • Unique da
Slide 7: New Key Hires Driving Global Expansion
New Key Hires Driving Global Expansion Dr. Faiçal Miyara Jim Ziegler Chief Business Officer Chief Commercial Officer • 20+ years in oncology BD, S&E, and venture investing across • 25+ years of commercial biopharma leadership including leading, global pharmaceutical and biotech companies hematology-
Slide 8: R&D Highlights
2 R&D Highlights 8
Slide 9: Lisaftoclax is Actively Advancing its Global Phase III Registrational Trials
Lisaftoclax is Actively Advancing its Global Phase III Registrational Trials Dose Escalation/ Clinical Program Indication Clinical POC Registrational Trial Marketed Dose Expansion Pivotal Ph-II CLL/SLL1 Single-agent Approved CLL/SLL sub-optimal BTKi FDA, EMA, and CDE cleared Global Phase III GLORA r
Slide 10: Rapid 5-day dose ramp-up and no prior lead-in for combination with BTKi
Rapid 5-day dose ramp-up and no prior lead-in for combination with BTKi Venetoclax Lisaftoclax Achieves target dose in just 5 days 5-week dose escalation 3-Cycle Prior Target Dose Maintenance BTKi Lead-in 200mg 400mg Dose escalation phase 20mg 50mg 100mg Therapy Day 1-5 Day 6 & Onwards Week 1 Week 2
Slide 11: Favorable Safety Profile and Better Drug Combinability
Favorable Safety Profile and Better Drug Combinability CLL/SLL and MCL Infection Rate Comparison PK Variability with Strong CYP3A4 Inhibitors 36% 11x 31% 26% 7.9x 19% 19% 2.4x 10% 12% 10% AUC 4% • Strong CYP3A inhibitors contraindicated with Ven and Sonro Infectious Upper Respiratory ≥Grade 3 Infect
Slide 12: Lisaftoclax Demonstrated Clinical Activity in MDS/CMML
Lisaftoclax Demonstrated Clinical Activity in MDS/CMML Across Clinical and Real-World Settings Efficacy Efficacyin Newly Diagnosed and R/R MDS/CMML in MDS/CMML Real-World Evidence Safety • 100% Among 3 patients with MDS, 2 (67%) achieved • TEAEs of any grade occurred in 87% of patients (26/30) Repre
Slide 13: Lisaftoclax Demonstrated Strong Clinical Activity in AML, Including Venetoclax Failed AML
Lisaftoclax Demonstrated Strong Clinical Activity in AML, Including Venetoclax Failed AML Efficacy in AML/MPAL, EHA 2026 Update including Venetoclax Failed AML 100% 90% ORR: 83.3% 72% 61% 80% Overall CR/CRi rate MRD negativity rate 70% CR: n=12; CRi: n=6 Correlated with response depth 60% 50.0% 50%
Slide 14: Olverembatinib is Actively Advancing its Global Phase III Registrational Trials
Olverembatinib is Actively Advancing its Global Phase III Registrational Trials Dose Escalation/ Clinical Program Indications Clinical POC Registrational Trials Marketed Dose Expansion CML-CP with/without T315I Marketed Pivotal Ph-II Mutation; CML-AP with T315I Single-agent Full approval and full co
Slide 15: Olverembatinib: Favorable Clinical Benefit and Tolerability in Heavily Pretreated CML-CP Patients
Olverembatinib: Favorable Clinical Benefit and Tolerability in Heavily Pretreated CML-CP Patients Phase 1b study in heavily pretreated CML-CP patients in the U.S. (N=62) Heavily Pretreated Patient Population 52% received ≥4 prior TKIs 50% ponatinib-pretreated 27% asciminib-pretreated 29% with T315I
Slide 16: Olverembatinib: Potential Best-In-Class TKI in Later Line CML Patients
Olverembatinib: Potential Best-In-Class TKI in Later Line CML Patients Olverembatinib in 2L CML-CP patients Olverembatinib in 2L+ CML-CP patients (32/42) (20/42) (19/35) (7/70) (20/35) (15/70) 100% 100% PƟ0.001 90% 90% 80% 76.2% 80% 70% 70% 60% 60% 54.3% 57.1% 50% 47.6% 50% 40% 40% 30% 30% 21.4% 20%
Slide 17: Olverembatinib: Proven Activity After Ponatinib and Asciminib Failure in CML
Olverembatinib: Proven Activity After Ponatinib and Asciminib Failure in CML Peer Benchmarking Analysis Olverembatinib ELVN-001 TERN-701 Key Takeaways Approved and • Long-term, post-approval evidence: four- and six- Stage of development Phase 1b Phase 1/2 marketed year follow-up, with thousands of p
Slide 18: Deep Remission, Improvement in Allo-HSCT Outcomes in BC-CML patients
Deep Remission, Improvement in Allo-HSCT Outcomes in BC-CML patients Real-world analysis of 69 patients receiving 1/2G TKIs (n=43) or olverembatinib (n=26) before transplantation 1/2G TKIs Olverembatinib Deeper Molecular Remission at Transplantation Favorable Survival Outcomes MMR 1-Year Overall Sur
Slide 19: Olverembatinib: Emerging Backbone Therapy in Ph+ Leukemias
Olverembatinib: Emerging Backbone Therapy in Ph+ Leukemias Olverembatinib + Olverembatinib + Olverembatinib + Low-Intensity Chemotherapy Blinatumomab Lisaftoclax Frontline Ph+ ALL CML-LBP and Ph+ BCP-ALL Pediatric R/R Ph+ ALL 63% 80% 89% MRD-negative CR rate MRD-negative by flow cytometry (10 −4 ) O
Slide 20: Alrizomadlin (APG-115): Orally Bioavailable, Highly Selective MDM2-p53 Inhibitor
Alrizomadlin (APG-115): Orally Bioavailable, Highly Selective, Small Molecule Inhibitor Targeting MDM2-p53 Clinical scope spans multiple rare oncology settings: ACC MPNST AML/MDS Pediatric solid tumors Mechanism of Action APG-115 Overview Strategic Validation 6 FDA Orphan Drug Designations • Ipsen /
Slide 21: Alrizomadlin Alone or Combo Lisaftoclax in Pediatric Rhabdomyosarcomas or STSs
Alrizomadlin Alone or Combo Lisaftoclax Demonstrated Encouraging Objective Response Rates in Pediatric Patients with Rhabdomyosarcomas or STSs Efficacy of Alrizomadlin + Lisaftoclax in patients with RMS and other tumors 23.5% ORR including 1 CR, 3 PRs 70.6% DCR 12 patients achieved PR or SD 2 of 7 R
Slide 22: Lisaftoclax - Cornerstone Asset in Hematologic Malignancies
Lisaftoclax - Cornerstone Asset in Hematologic Malignancies Opportunity For Highly Impactful Therapeutic Synergy Lisaftoclax Potential Best-In-Class Bcl-2 Selective Inhibitor Olverembatinib APG-3288 Multiple Hematologic 3G BCR-ABL BTK protein Malignancies · Inhibitor degrader Autoimmune Diseases Pot
Slide 23: Financial Results
Kscentage Financial Results
Slide 24: Continued Commercial Execution in 1H 2026
Continued Commercial Execution in 1H 2026 ($ in U.S. millions) Total revenue R&D expense S&D expense $102.8 29% $73.8 $44.5 $62.0 61% $32.6 $33.4 $20.0 $19.2 $12.5 1H 20241 1H 2025 1H 2026 1H 2024 1H 2025 1H 2026 1H 2024 1H 2025 1H 2026 Revenue grew 29% YoY1 to US$44.5 million, Increase in R&D e
Slide 25: 2026 Interim Reported Consolidated Balance Sheet
2026 Interim Reported Consolidated Balance Sheet ,Q86'µ 30-Jun-26 31-Dec-25 Assets Cash and bank balances $279,374 $353,217 Prepayments, deposits and other receivables 18,432 20,847 Other current assets 40,179 46,947 Property, plant and equipment 110,760 111,715 Intangible assets 5,537 9,429 Other n
Slide 26: Patient-Centric Innovation; Global Breakthrough Therapies
Patient-Centric Innovation; Global Breakthrough Therapies CML DLBCL /TCL Pelcitoclax ALL APG-3288 (APG-1252) APG-2449 Major MM Hematology Alrizomadlin Malignancy (APG-115) APG-5918 CLL AML MDS Olverembatinib Lisaftoclax
Slide 27: Ascentage
Kscentage 27
Ascentage Pharma Group International — Q2 2026 Earnings Presentation on 6ix